Physician profile
Thomas E Carson
NPI 1427058791
$3,712.47
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $1,509 · 2021: $236.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $720.99 | 2019-2021 | |
| Lilly USA, LLC | $385.03 | 2019-2021 | |
| Pfizer INC. | $357.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.98 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $219.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $216.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $200.46 | 2019-2020 | |
| Amarin Pharma, INC. | $195.20 | 2019-2020 | |
| Novo Nordisk INC | $145.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $127.00 | 2019-2021 | |
| Silk Road Medical, INC. | $96.24 | 2020 | |
| Allergan, INC. | $93.99 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $76.28 | 2019-2020 | |
| Astellas Pharma US INC | $73.17 | 2019-2020 | |
| Amgen INC. | $69.21 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.34 | 2019-2021 | |
| Eisai INC. | $53.82 | 2020 | |
| Sanofi-Aventis U.S. LLC | $44.03 | 2019-2020 | |
| Abbvie INC. | $42.74 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $40.91 | 2019-2020 | |
| Esperion Therapeutics, INC. | $30.51 | 2020 | |
| Coloplast Corp | $30.20 | 2019 | |
| Boston Scientific Corporation | $24.70 | 2019 | |
| Valeritas, INC. | $19.92 | 2019 | |
| Medtronic Vascular, INC. | $13.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.92 | 2019 | |
| Currax Pharmaceuticals LLC | $12.91 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.61 | 2019 | |
| Sanofi Pasteur INC. | $11.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.